STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2 Line 27	Abstract Para 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2 Line 27-47	Abstract Para 1-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4 Line 78-102	Introduction Para 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5 Line 103-106	Introduction Para 3
Methods				
Study design	4	Present key elements of study design early in the paper	Page 5 Line 111-113	Methods Para 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5 Line 111-116	Methods Para 1-2
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 5 Line 111-116	Methods Para 1-2
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A	This study is not a matched study.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5-6 Line 114-132	Methods Para 2
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 5-6 Line 114-133	Methods Para 2
Bias	9	Describe any efforts to address potential sources of bias	Page 5 Line 111-113	Methods Para 1
Study size	10	Explain how the study size was arrived at	Page 5 Line 111-113	Methods Para 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 5 Line117-124	Methods Para 2

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 6 Line 134-135	Methods Para 2
		(b) Describe any methods used to examine subgroups and interactions	N/A	There are no subgroups.
		(c) Explain how missing data were addressed	N/A	No missing data.
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A	This study does not involve the analysis of this aspect.
		(e) Describe any sensitivity analyses	N/A	Not applicable.
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 6 Line 137-143	Results Para 1
		(b) Give reasons for non-participation at each stage	Page 6 Line 137-143	Results Para 1
		(c) Consider use of a flow diagram	N/A	Only 1 step exclusion.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 14-15, Table 1-2	Results, Tables
		(b) Indicate number of participants with missing data for each variable of interest	N/A	No missing data.
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 6 Line 137-140	Results Para 1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 6-7 Line 146-181	Results Para 1-4
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	This is a cohort study.
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	This is a cohort study.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A	This study does not involve adjusted
		(b) Report category boundaries when continuous variables were categorized	N/A	This study does not
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	This study does not
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	This study does not
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 8 Line 184-229	Conclusion Para 1-5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 9-10 Line 230-242	Conclusion Para 6

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 10 Line 243-250	Conclusion Para 7
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 10 Line 245-250	Conclusion Para 7
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 11 Line 262	Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-22-300
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.